Gilead Sciences (GILD) news
Recent news
Lakefront Biopharma NV - Gamgertamig in Phase 2 studies; registration studies expected in 2027
Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) has announced that gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, is currently in Phase 2 studies and enter registrational studies as early as 2027. The drug candidate, which has been granted both Fast Track and Orphan Drug…
AInvest Wire · 6d agoImportantGilead's Trodelvy gets EU nod in 1L PD-L1+ metastatic TNBC
AInvest Wire · 7d agoKeymed Biosciences announces 2026 H1 results and business updates
Keymed Biosciences (HKEX: 02162) reported its 2026 first-half financial results, showing strong revenue growth and improved profitability. For the six months ended June 30, 2026, the company recorded sales of RMB 617.07 million, representing a 23.7% year-on-year increase compared to RMB 498.75…
AInvest Wire · Aug 20, 2026Mubadala Investment Co PJSC cuts share stake in Gilead Sciences Inc by 19.9% to 29,623 shares - SEC filing
AInvest Wire · Aug 14, 2026Leerink Partners cuts target price to $60 from $72
Leerink Partners has revised its price target for a stock previously set at $72, reducing it to $60 . The adjustment reflects a reassessment of market conditions or company-specific factors, though specific details regarding the rationale for the change were not disclosed in the available…
AInvest Wire · Aug 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.